Real-World Data on the Efficacy and Safety of Fexuprazan in Patients with Gastroesophageal Reflux Disease: Interim Analysis of Post-Marketing Surveillance
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background/Aims: Fexuprazan, a novel potassium-competitive acid blocker, has emerged as a promising alternative to proton pump inhibitors for the treatment of gastroesophageal reflux disease (GERD). Although its efficacy has been confirmed in clinical trials, real-world evidence on fexuprazan safety and effectiveness, particularly in older populations, remains limited. This interim analysis of a post-marketing surveillance study was conducted to evaluate the safety and clinical effectiveness of fexuprazan in patients with GERD under routine clinical conditions. Methods: A total of 671 case report forms were collected from multiple centers in Korea. After excluding ineligible cases, 630 patients were included in the safety analysis set, and 588 patients who completed at least 4 weeks of treatment were analyzed for the efficacy of fexuprazan. Symptom improvement and changes in GERD health-related quality of life (GERD-HRQL) scores were assessed. Adverse events and adverse drug reactions (ADRs) were monitored and compared across age groups. Results: Among the 630 patients, 294 (46.7%) were aged ≥65 years, and 88 (14.0%) were aged ≥75 years. Symptom improvement was observed in 95.75% of the patients, with no significant differences among age groups. The GERD-HRQL scores improved from 13.3±9.5 at baseline to 3.0±4.4 after treatment. The overall incidence of ADRs was 2.38%, and no serious ADRs were reported, with no notable age-related differences. Conclusions: Fexuprazan demonstrated consistent efficacy with a favorable safety profile in the real-world management of GERD, including in older patients. These interim results support the use of fexuprazan as a safe and effective treatment option, including in older patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-World Data on the Efficacy and Safety of Fexuprazan in Patients with Gastroesophageal Reflux Disease: Interim Analysis of Post-Marketing Surveillance
- Date Crossref
- 10/06/2026
- Éditeur
- The Editorial Office of Gut and Liver
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Yonsei University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Samsung Medical Center pays non établi dans la noticeÉtablissement de santé
-
Gangnam Severance Hospital pays non établi dans la noticeÉtablissement de santé
-
Sungkyunkwan University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Chonnam National University Hospital Department of Cardiovascular Medicine pays non établi dans la noticeÉtablissement de santé
-
Hallym University Medical Center Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Inje University Haeundae Paik Hospital pays non établi dans la noticeÉtablissement de santé
-
Naju National Hospital pays non établi dans la noticeÉtablissement de santé
-
Daewoo Electronics (South Korea) pays non établi dans la noticeEntreprise
-
Daewoo Pharma (South Korea) pays non établi dans la noticeEntreprise
-
Yeungnam University College Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Yeungnam University pays non établi dans la noticeUniversité ou école supérieure
Department of Internal Medicine — Yonsei University, Samsung Medical Center et Gangnam Severance Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.